Prevent Senior did not tell patients who died that they

Prevent Senior has not informed its covid-19 patients that they will be on hydroxychloroquine and ivermectin. The research, which began on March 25, 2020, two weeks after the World Health Organization (WHO) announced the coronavirus pandemic, was hidden from patients and their families.

In a message sent to Prevent Senior employees, Fernando Oikawa, director of the health plan, says.

“We will start the hydroxychloroquine and ivermectin protocol. Please do not inform the patient or family member about the medication or the program.”

Prevent Senior’s omission was revealed by GloboNews this Thursday (16). According to the broadcaster, the health plan lied in the report about the research carried out on people infected with covid-19. In the final text, the company stated that only two patients died after the combined use of the drugs. In fact, there were nine.

The survey of Prevent Senior’s patients was supported by President Jair Bolsonaro (non-party) and the results pointed out by the study were used by advocates of the drugs, which remain without scientific proof.

Os primeiros resultados da pesquisa foram divulgados pela Prevent Senior em 15 de abril de 2020. Três dias depois, em sua conta pessoal no Twitter, Bolsonaro divulgou o estudo feito pelo plano de saúde.

“Out of a group of 636 patients followed by doctors, 224 did not use hydroxychloroquine. Of these, 12 were hospitalized and 5 died. Of the 412 who opted for the drug, only 8 were hospitalized and, in addition to not being intubated, the number of deaths was zero. The full study will be published shortly”, said the president.

The dossier, with a series of complaints against Prevent Senior, based on testimony from doctors and former doctors of the health plan, is already with the CPI of the Pandemic, which investigates the role of the federal government in conducting the crisis generated by the coronavirus in the parents.

In a note, Prevent Senior informed that it has always acted within ethical and legal parameters.

Edition: Anelize Moreira

Deixe um comentário

O seu endereço de e-mail não será publicado. Campos obrigatórios são marcados com *